Incidence, morbidity, and costs of human metapneumovirus infection in hospitalized children

Journal of the Pediatric Infectious Diseases Society

Volumn 5, Issue 3, 2016, Pages 303-311

  Davis, Carly R ^a   Stockmann, Chris ^a   Pavia, Andrew T ^a   Byington, Carrie L ^a   Blaschke, Anne J ^a   Hersh, Adam L ^a   Thorell, Emily A ^a   Korgenski, Kent ^a,b   Daly, Judy ^b   Ampofo, Krow ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

Complications; Disease severity; HMPV; Hospital cost; Human metapneumovirus

Indexed keywords

VACCINE;

ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; BRONCHIOLITIS; CHILD; HOSPITAL COST; HOSPITALIZATION; HOSPITALIZED CHILD; HUMAN; HUMAN METAPNEUMOVIRUS INFECTION; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORBIDITY; PERIODICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VIRUS PNEUMONIA; COMORBIDITY; ECONOMICS; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; METAPNEUMOVIRUS; PARAMYXOVIRUS INFECTION; SEASON; UTAH;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HOSPITAL COSTS; HUMANS; INCIDENCE; INFANT; LENGTH OF STAY; MALE; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; PERIODICITY; RETROSPECTIVE STUDIES; SEASONS; UTAH;

EID: 84995575827     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piv027     Document Type: Article

References (57)

1. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-24.
2. Esper F, Martinello RA, Boucher D, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis 2004; 189:1388-96.
3. McAdam AJ, Hasenbein ME, Feldman HA, et al. Human metapneumovirus in children tested at a tertiary-care hospital. J Infect Dis 2004; 190:20-6.
4. Gray GC, Capuano AW, Setterquist SF, et al. Multi-year study of human metapneumovirus infection at a large US Midwestern Medical Referral Center. J Clin Virol 2006; 37:269-76.
5. Crowe JE Jr. Human metapneumovirus as a major cause of human respiratory tract disease. Pediatr Infect Dis J 2004; 23 (11 Suppl):S215-21.
6. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. New Engl J Med 2004; 350:443-50.
7. Boivin G, De Serres G, Cote S, et al. Human metapneumovirus infections in hospitalized children. Emerg InfectDis 2003; 9:634-40.
8. Nissen MD, Siebert DJ, Mackay IM, et al. Evidence of human metapneumovirus in Australian children. Med J Aust 2002; 176:188.
9. Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis 2002; 8:897-901.
10. Chung JY, Han TH, Kim BE, et al. Human metapneumovirus infection in hospitalized children with acute respiratory disease in Korea. J Korean Med Sci 2006; 21:838-42.
11. Ordas J, Boga JA, Alvarez-Arguelles M, et al. Role of metapneumovirus in viral respiratory infections in young children. J Clin Microbiol 2006; 44:2739-42.
12. Peiris JS, Tang WH, Chan KH, et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003; 9:628-33.
13. Wolf DG, Greenberg D, Kalkstein D, et al. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J 2006; 25:320-4.
14. Williams JV, Edwards KM, Weinberg GA, et al. Population-based incidence of human metapneumovirus infection among hospitalized children. J Infect Dis 2010; 201:1890-8.
15. Leung J, Esper F, Weibel C, Kahn JS. Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus. J Clin Microbiol 2005; 43:1213-9.
16. Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000; 283:499-505.
17. Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis 1994; 18:770-9.
18. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratoryconfirmed influenza infection. Pediatrics 2006; 118:2409-17.
19. Neuzil K, Mellen B, Wright P, et al. The effect of influenza on hospitalizations, outpatients visits, and courses of antibiotics in children. New Engl J Med 2000; 342:225-31.
20. Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Tar 2012; 12:92-7.
21. Feudtner C, Christakis DA, Connell FA. Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington State, 1980-1997. Pediatrics 2000; 106(1 Pt 2):205-9.
22. Hahn A, WangW, Jaggi P, et al. Human metapneumovirus infections are associated with severe morbidity in hospitalized children of all ages. Epidemiol Infect 2013; 141:2213-23.
23. Principi N, Esposito S. Paediatric human metapneumovirus infection: epidemiology, prevention and therapy. J Clin Virol 2014; 59:141-7.
24. Classen D, Pestotnik S, Evans R, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277:301-6.
25. Harbarth S, Burke J, Lloyd J, et al. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002; 35:e120-7.
26. Oderda G, Evans R, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manage 2003; 25:276-83.
27. U.S. Bureau of Labor Statistics. CPI Inflation Calculator. Available at: http://www.bls.gov/cpi/home.htm. Accessed 2 September 2014.
28. Population EstimatesQuery Module for Utah Counties and Local Health Districts. Available at: http://www.pandemicflu.utah.gov/query/selection/pop/PopSelection.html. Accessed 30 June 2014.
29. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. New Engl J Med 2006; 355:31-40.
30. Nicholson KG, McNally T, Silverman M, et al. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006; 24:102-8.
31. Foulongne V, Guyon G, Rodiere M, Segondy M. Human metapneumovirus infection in young children hospitalized with respiratory tract disease. Pediatr Infect Dis J 2006; 25:354-9.
32. Sloots TP, Mackay IM, Bialasiewicz S, et al. Human metapneumovirus, Australia, 2001-2004. Emerg Infect Dis 2006; 12:1263-6.
33. Heikkinen T, Osterback R, Peltola V, et al. Human metapneumovirus infections in children. Emerg Infect Dis 2008; 14:101-6.
34. Aberle SW, Aberle JH, Sandhofer MJ, et al. Biennial spring activity of human metapneumovirus in Austria. Pediatr Infect Dis J 2008; 27:1065-8.
35. Heininger U, Kruker AT, Bonhoeffer J, Schaad UB. Human metapneumovirus infections-biannual epidemics and clinical findings in children in the region of Basel, Switzerland. Eur J Pediatr 2009; 168:1455-60.
36. Aberle JH, Aberle SW, Redlberger-Fritz M, et al. Human metapneumovirus subgroup changes and seasonality during epidemics. Pediatr Infect Dis J 2010; 29:1016-8.
37. Boivin G, Abed Y, Pelletier G, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002; 186:1330-4.
38. Eggleston HA, Gunville CF, Miller JI, et al. A comparison of characteristics and outcomes in severe human metapneumovirus and respiratory syncytial virus infections in children treated in an intensive care unit. Pediatric Infect Dis J 2013; 32:1330-4.
39. Mullins JA, Erdman DD, Weinberg GA, et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis 2004; 10:700-5.
40. Akhras N, Weinberg JB, Newton D. Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity. Infect Dis Rep 2010; 2:e12.
41. Dawood FS, Chaves SS, Perez A, et al. Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010. J Infect Dis 2014; 209:686-94.
42. Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 2007; 119: 740-8.
43. Bloomfield P, Dalton D, Karleka A, Kesson A, Duncan G, Isaacs D. Bacteraemia and antibiotic use in respiratory syncytial virus infections. Arch Dis Child. 2004; 89:363-7.
44. Rocholl C, Gerber K, Daly J, Pavia A, Byington C. Adenoviral infection in children: The impact of rapid diagnosis. Pediatrics 2004; 113:e51-e6.
45. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis. 2003; 187:1000-9.
46. Iverson AR, Boyd KL, McAuley JL, Plano LR, Hart ME, McCullers JA. Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis. 2011; 203:880-8.
47. Ampofo K, Bender J, Sheng X, et al. Seasonal invasive pneumococcal disease: Role of preceding respiratory viral infection. Pediatrics 2008; 122.
48. Peterson CL, Vugia DJ, Meyers HB, et al. Risk factors for invasive group A streptococcal infections in children with varicella: a casecontrol study. Pediatr Infect Dis J. 1996; 15:151-6.
49. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006; 295:1668-74.
50. Edwards KM, Zhu Y, Griffin MR, et al. Burden of human metapneumovirus infection in young children. New Engl J Med 2013; 368:633-43.
51. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004-2009. Pediatrics 2013; 131: 207-16.
52. Cilla G, Onate E, Perez-Yarza EG, et al. Hospitalization rates for human metapneumovirus infection among 0-to 3-year-olds in Gipuzkoa (Basque Country), Spain. Epidemiol Infect 2009; 137:66-72.
53. Fairbrother G, Cassedy A, Ortega-Sanchez IR, et al. High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine 2010; 28:4913-9.
54. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. PharmacoEconomics 2004; 22: 275-84.
55. Herfst S, Schrauwen EJ, de Graaf M, et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine 2008; 26:4224-30.
56. Cseke G, Wright DW, Tollefson SJ, et al. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 2007; 81:698-707.
57. Levy C, Aerts L, Hamelin ME, et al. Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. Vaccine 2013; 31:2778-85.